Cortagen: Cardiovascular Peptide Bioregulator Research Overview
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
What Is Cortagen?
Cortagen (Lys-Glu-Asp, also known as KED) is a synthetic tripeptide bioregulator developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It is derived from cardiac tissue and is specifically designed to target cardiovascular cells. Cortagen is part of the same family of short peptide bioregulators as Epithalon, Pinealon, and Vilon, each targeting different organ systems.
Mechanism of Action
Like other Khavinson peptide bioregulators, Cortagen acts through an epigenetic mechanism — binding to DNA regulatory sequences and modulating gene expression in cardiac and vascular cells. Research shows Cortagen influences the expression of:
| Gene Category | Effect | |--------------|--------| | Antioxidant enzymes | Upregulation | | Anti-apoptotic proteins | Upregulation | | Inflammatory mediators | Downregulation | | Collagen synthesis | Modulation | | Vascular tone regulators | Normalization |
Cardioprotective Research
Cortagen has been studied in models of cardiac injury and ischemia. Key research findings include protection against cardiomyocyte apoptosis following ischemia-reperfusion injury, reduction in oxidative stress markers in cardiac tissue, and preservation of mitochondrial function under hypoxic conditions. These effects suggest potential relevance to research on myocardial infarction recovery and cardiac aging.
Vascular Effects
Research on Cortagen's vascular effects shows improvements in endothelial function, reduction in vascular inflammation markers, and modulation of vascular smooth muscle cell proliferation. These effects are relevant to research on atherosclerosis, hypertension, and age-related vascular stiffening.
Aging and Cardiovascular Research
Cardiovascular aging is characterized by increased arterial stiffness, reduced cardiac reserve, and increased susceptibility to ischemic injury. Cortagen has been studied in aged animal models, showing improvements in cardiac function parameters and vascular compliance. In long-term studies, Cortagen administration was associated with reduced cardiovascular pathology and extended lifespan in aged rats.
Comparison With Other Cardiovascular Peptides
| Peptide | Mechanism | Primary Cardiovascular Effect | |---------|-----------|------------------------------| | Cortagen | Epigenetic, cardiac-targeted | Cardioprotection, anti-aging | | TB-500 | Actin/angiogenesis | Cardiac repair post-MI | | BPC-157 | NO system, VEGF | Vascular repair, anti-arrhythmic | | GHK-Cu | Collagen synthesis | Vascular wall integrity |
Research Limitations
Cortagen research is primarily from Russian institutions and preclinical animal models. Independent replication in Western research settings is limited. Human clinical data is sparse. These limitations should be considered when interpreting research findings and designing studies.
Key Research Takeaways
Cortagen represents a specialized research tool for studying cardiovascular epigenetics and cardiac aging. Its tissue-specific targeting and epigenetic mechanism distinguish it from receptor-mediated cardiovascular peptides. For researchers studying cardiac aging, ischemia-reperfusion injury, or vascular biology, Cortagen offers a unique mechanistic angle with a growing preclinical evidence base.
Was this article helpful?
Click a star to rate